Allscripts has been included on a new list of accredited suppliers of electronic patient records that has been published by NHS England and NHSX. The company is one of just eight vendors listed on lot one of the Health Systems Support Framework, which is expected to become one of the main routes for NHS trusts to procure digital services, software and infrastructure. 
Isansys Lifecare is proud to announce it has been shortlisted in the Most Transformative Digital Healthcare Company category at the OBN Annual Awards 2019. The award recognises the significant uptake of the technology by healthcare providers and the real impact Isansys' technology is having on patients and hospitals globally. 
Siemens Healthineers AG has entered into a merger agreement with U.S.-based Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a global technology leader for robotic-assisted vascular interventions. Under the terms of the agreement, Siemens Healthineers will acquire all fully diluted shares of Corindus for $4.28 per share in cash or $1.1 billion in total. 
Initial results from a feasibility study conducted by Eli Lilly and Company (NYSE: LLY), Evidation Health, and Apple Inc. (NASDAQ: AAPL) showed that an iPhone, Apple Watch, iPad and the Beddit sleep monitoring device, in combination with digital apps may be able to differentiate people with mild cognitive impairment (MCI) and mild Alzheimer's disease dementia. 
IMS MAXIMS has secured a place on a framework contract established by NHS England to make it easier for healthcare economies to buy the IT they need for transformation and integration projects.
The company has secured a place on lot one of the Health Systems Support Framework, which covers electronic patient records for acute and mental health trusts.
As part of a technology partnership between the two organizations, Siemens Healthineers and the Herz- und Diabeteszentrum Nordrhein-Westfalen (Heart and Diabetes Center North Rhine-Westphalia, HDZ NRW) in Bad Oeynhausen have developed their first innovative care service for patients with cardiovascular diseases. 
Opinion Article by Erik Janssen, VP, Innovative Solutions, Neurology, UCB Pharma.